Citi lowered the firm’s price target on Ultragenyx to $126 from $133 and keeps a Buy rating on the shares as part of a broader research note on U.S. Biotechnology. The analyst is citing the impact from the company’s recent financing in updating the firm’s model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RARE:
- Ultragenyx price target lowered to $74 from $76 at JPMorgan
- Ultragenyx to Participate at Investor Conferences in November
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Biotech Alert: Searches spiking for these stocks today
- Ultragenyx to Participate in the Jefferies London Healthcare Conference